Together with an expanded understanding of the Hippo-YAP pathway in human cancer, the development of specific YAP/TAZ inhibitors with high potency can provide a new breakthrough in targeted therapeutic approaches to HNSCC. This evidence concerns the gene YAP1 and head and neck squamous cell carcinoma.